US Bancorp DE Has $32.42 Million Holdings in Edwards Lifesciences Corporation $EW

Key Points

• US Bancorp DE has reduced its stake in Edwards Lifesciences Corporation by 10.2%, currently holding 414,455 shares valued at approximately $32.42 million.
• Edwards Lifesciences received multiple upgrades from analysts, with price targets increasing to an average of $87.06, indicating a consensus rating of "Moderate Buy."
• The company reported strong quarterly earnings results, with $1.53 billion in revenue, surpassing estimates and showing an 11.9% year-over-year increase.

US Bancorp DE lowered its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 10.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 414,455 shares of the medical research company's stock after selling 46,944 shares during the period. US Bancorp DE owned approximately 0.07% of Edwards Lifesciences worth $32,415,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Jennison Associates LLC lifted its position in shares of Edwards Lifesciences by 34.3% in the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock worth $731,036,000 after buying an additional 2,576,383 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Edwards Lifesciences by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company's stock worth $491,673,000 after purchasing an additional 264,311 shares during the last quarter. Nuveen LLC acquired a new position in shares of Edwards Lifesciences during the 1st quarter worth about $330,881,000. Invesco Ltd. lifted its position in shares of Edwards Lifesciences by 2.6% during the 1st quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company's stock worth $310,773,000 after purchasing an additional 107,241 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Edwards Lifesciences by 5.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company's stock worth $287,140,000 after purchasing an additional 198,882 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on EW shares. Daiwa America raised Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 29th. BTIG Research raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price objective for the company in a research report on Tuesday, July 29th. Robert W. Baird boosted their price objective on Edwards Lifesciences from $78.00 to $79.00 and gave the stock a "neutral" rating in a research report on Friday, July 25th. Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a research report on Friday, July 25th. Finally, Morgan Stanley upped their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a report on Tuesday, July 15th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of "Moderate Buy" and an average target price of $87.06.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Trading Down 1.6%

EW stock opened at $74.02 on Friday. Edwards Lifesciences Corporation has a 1-year low of $64.89 and a 1-year high of $83.00. The firm has a market cap of $43.46 billion, a P/E ratio of 10.65, a P/E/G ratio of 3.61 and a beta of 1.05. The business's 50 day moving average is $78.09 and its 200-day moving average is $76.10. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the company posted $0.70 EPS. The company's revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.